- Home
- NN vs SUPN Comparison
NN vs SUPN Comparison
Compare NN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NN
- SUPN
- Stock Information
- Founded
- NN 2007
- SUPN 2005
- Country
- NN United States
- SUPN United States
- Employees
- NN N/A
- SUPN N/A
- Industry
- NN Industrial Machinery/Components
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- NN Industrials
- SUPN Health Care
- Exchange
- NN Nasdaq
- SUPN Nasdaq
- Market Cap
- NN 1.8B
- SUPN 1.8B
- IPO Year
- NN N/A
- SUPN 2012
- Fundamental
- Price
- NN $11.86
- SUPN $33.15
- Analyst Decision
- NN
- SUPN Hold
- Analyst Count
- NN 0
- SUPN 2
- Target Price
- NN N/A
- SUPN $36.00
- AVG Volume (30 Days)
- NN 1.3M
- SUPN 418.1K
- Earning Date
- NN 08-06-2025
- SUPN 05-06-2025
- Dividend Yield
- NN N/A
- SUPN N/A
- EPS Growth
- NN N/A
- SUPN N/A
- EPS
- NN N/A
- SUPN 1.11
- Revenue
- NN $6,162,000.00
- SUPN $667,997,000.00
- Revenue This Year
- NN $18.26
- SUPN N/A
- Revenue Next Year
- NN $4.59
- SUPN $9.04
- P/E Ratio
- NN N/A
- SUPN $29.95
- Revenue Growth
- NN 51.10
- SUPN 11.82
- 52 Week Low
- NN $6.47
- SUPN $25.53
- 52 Week High
- NN $18.54
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- NN 43.69
- SUPN 58.75
- Support Level
- NN $10.84
- SUPN $31.32
- Resistance Level
- NN $12.02
- SUPN $32.85
- Average True Range (ATR)
- NN 0.75
- SUPN 0.67
- MACD
- NN -0.18
- SUPN 0.04
- Stochastic Oscillator
- NN 31.48
- SUPN 82.06
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.